Also in this study, we found that ~50%‐60% of COVID‐19 convalescent patients have antibodies inhibiting the binding of RBD to ACE2 and hence may be considered to have neutralizing capacity, which confirmed the findings of our last study9 (data not shown). The gene discussed is ACE2; the disease is COVID-19.